Clinical trial
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
NCT00035789 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2001
- Completion date
- May 31, 2005
- Enrollment
- Not reported
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b